Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Jing L. Marantz Sells 5,655 Shares

Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report) insider Jing L. Marantz sold 5,655 shares of the firm's stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $44.20, for a total transaction of $249,951.00. Following the completion of the transaction, the insider now directly owns 67,200 shares in the company, valued at approximately $2,970,240. The trade was a 7.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Scholar Rock Stock Up 4.1 %

Shares of Scholar Rock stock traded up $1.75 on Tuesday, hitting $44.88. The company had a trading volume of 1,004,933 shares, compared to its average volume of 1,009,194. Scholar Rock Holding Co. has a twelve month low of $6.76 and a twelve month high of $46.19. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. The stock has a 50-day moving average of $39.58 and a 200-day moving average of $23.33. The firm has a market capitalization of $4.20 billion, a P/E ratio of -19.10 and a beta of 0.52.

Hedge Funds Weigh In On Scholar Rock

A number of large investors have recently added to or reduced their stakes in SRRK. GAMMA Investing LLC boosted its position in shares of Scholar Rock by 51.8% during the fourth quarter. GAMMA Investing LLC now owns 788 shares of the company's stock worth $34,000 after buying an additional 269 shares during the period. JPMorgan Chase & Co. boosted its position in Scholar Rock by 1.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company's stock worth $310,000 after acquiring an additional 379 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Scholar Rock by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company's stock worth $25,000 after acquiring an additional 514 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Scholar Rock by 1,321.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock valued at $48,000 after purchasing an additional 1,031 shares during the last quarter. Finally, Cinctive Capital Management LP grew its position in Scholar Rock by 7.2% in the third quarter. Cinctive Capital Management LP now owns 42,902 shares of the company's stock valued at $344,000 after purchasing an additional 2,869 shares in the last quarter. Institutional investors own 91.08% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. JPMorgan Chase & Co. raised their price target on Scholar Rock from $18.00 to $31.00 and gave the stock an "overweight" rating in a research report on Monday, October 14th. BMO Capital Markets raised their target price on Scholar Rock from $34.00 to $38.00 and gave the stock an "outperform" rating in a report on Friday, October 11th. Piper Sandler increased their price target on shares of Scholar Rock from $28.00 to $42.00 and gave the company an "overweight" rating in a research report on Tuesday, October 15th. Wedbush restated an "outperform" rating and set a $47.00 price objective on shares of Scholar Rock in a report on Thursday, January 9th. Finally, HC Wainwright increased their target price on shares of Scholar Rock from $40.00 to $50.00 and gave the stock a "buy" rating in a report on Tuesday, November 26th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Scholar Rock has a consensus rating of "Buy" and a consensus price target of $40.43.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.